
|Videos|March 1, 2022
Improvements in bone-metastasis-related pain and QoL demonstrated in mCRPC with Lutetium-177 PSMA-617
Author(s)Urology Times staff
Advertisement
In this video, Brian D. Gonzalez, PhD, discusses the background, findings, and takeaways of the study, “Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gonzalez is an associate member and quality of life researcher at Moffitt Cancer Center in Tampa, Florida.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












